First approved in 2009 for the treatment of renal cell carcinoma and expanded to include treatment of ER+HER2- metastatic breast cancer in combination with exemestane following progression on letrozole or anastrozole. Here, ESR1 is linked to hereditary clear cell renal cell carcinoma.